New Research Shows Lysoveta Enhances EPA and DHA Delivery to the Brain

A newly published study highlighted by Aker BioMarine, a developer of marine-based health ingredients, provides further evidence supporting the company’s omega-3 ingredient, Lysoveta, demonstrating its ability to deliver eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) to the brain, addressing a challenge in omega-3 supplementation. According to a news release from the company, the brain health ingredient Lysoveta, a lysophosphatidylcholine (LPC)-bound omega-3, is able to transport nutrients across the blood-brain barrier.¹

The ingredient is positioned as support for both long-term brain health and healthy aging. “With a growing burden of brain-related diseases like Alzheimer’s and dementia, research into how nutrition can support brain health has never been more important,” stated Matts Johansen, CEO of Aker BioMarine.

Delivering Nutrients to the Brain

The efficacy of Lysoveta lies in its molecular structure. The company explains that the brain recognizes DHA when it is in the form of LPC, so that by providing EPA and DHA in the LPC form, Lysoveta can leverage the MFSD2A pathway and cross the brain’s barriers.

Key Study Findings: Genotype-Specific Efficacy

The recent preclinical study, published in The Journal of Nutritional Biochemistry, underscores the potential of this ingredient to address challenges in cognitive health.²

The researchers tested the effect of the LPC-bound omega-3 fatty acids (or a control) over two or four months in APOE3 and APOE4 mice. The doses were 21.5 mg/day of EPA and 10.4 mg/day of DHA. The APOE4 gene is the strongest genetic risk factor for late-onset Alzheimer’s disease, Aker BioMarine notes.

The study’s findings included:

• Targeted Enrichment: Supplementation with Lysoveta resulted in significant enrichment of EPA and DHA in brain tissues
• Metabolic Activation: In APOE4 carriers, the study observed shifts in DHA-related metabolites. This indicates that Lysoveta can activate relevant neuro-pathways even in subjects where traditional omega-3 uptake is compromised

“Our results show that Lysoveta can enrich brain-related tissues with EPA and DHA, supporting its potential as a targeted nutritional strategy for brain health,” explained study author Mélanie Plourde from Université de Sherbrooke. “The distinct response observed in APOE4 further underscores the importance of genotype-specific approaches.”

Aker Biomarine noted that this is the third Lysoveta study demonstrating its neuroprotective effect through delivery of EPA and DHA to brain tissues.

“Each study brings us closer to understanding what Lysoveta can mean for brain health. The results so far are encouraging,” Johansen added. “As people live longer and the global population ages, the number of those affected by brain-related diseases will continue to rise and we need more research to address it.”

Commercial Implications for the Nutraceutical Industry

Aker Biomarine noted that the World Health Organization predicts that dementia cases will triple to 152 million by 2050, with risk factors such as aging populations, obesity, and diabetes also rising and attention to supporting brain health increasing.

Lysoveta was introduced in late 2020 after many years of research into phospholipids derived from krill. In an interview with Nutritional Outlook, Johansen further described the benefit categories for krill oil, moving beyond traditional support for heart and joint health into sports nutrition and healthy again. “We won't have high quality of life as we get older as well. So we’re looking at how we can make sure you stay mentally strong, how you can still continue to be fit as you grow older, and all of this is built on the phospholipid advantage found in omega-3s. Those phospholipids that are found in all the cells in your body incorporates that omega-3 directly into the cells in all parts of our body. And that's why we see those benefits across so many different areas.”

This article was created with assistance from AI. The content has been reviewed and edited by Erin McEvoy, Associate Editor. For more information on the extent and nature of AI usage, please contact us.

References

1. Dalsegg M. New Study Confirms Aker BioMarine’s Lysoveta Delivers EPA & DHA to the Brain. April 13, 2026. Accessed April 17, 2026. https://www.akerbiomarine.com/news/new-study-confirms-aker-biomarines-lysoveta-delivers-epa-dha-to-the-brain
2. Bijou A, Vachon A, Dansereau M-A, Dumais E, Flamand N, Laurent B, et al.Brain DHA increases in APOE3, but not in APOE4 mice, despite robust brain EPA increase during LPC n-3 supplementation in both genotypes. The Journal of Nutritional Biochemistry. Published online April 8, 2026; doi: 10.1016/j.jnutbio.2026.110376.
3. Krawiec S. Krill oil potential with Aker BioMarine. March 7, 2025. Accessed April 17, 2026. https://www.nutritionaloutlook.com/view/krill-oil-potential-with-aker-biomarine